Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from InhaleRx Limited ( (AU:NX1) ) is now available.
Nexalis Therapeutics has called its 2026 annual general meeting for 29 May as a virtual event, setting 27 May as the record date for shareholder voting eligibility. Investors are urged to review the company’s 2025 financial statements, directors’ declaration, remuneration report and auditor’s report ahead of the meeting.
Key items on the agenda include an advisory vote on the 2025 remuneration report and a potential spill resolution that could force a further shareholder meeting and board changes if investor support is sufficiently low. Shareholders will also vote on the re-election of director Dr Ron Wise, a routine governance step that nonetheless offers investors an opportunity to signal their confidence in current board leadership.
More about InhaleRx Limited
Nexalis Therapeutics Ltd is an Australia-based company whose shares are held by a broad base of investors. Listed on the ASX, it operates within the life sciences and therapeutics sector, with its governance and reporting obligations shaped by Australian corporate and securities regulations.
Average Trading Volume: 164,123
Technical Sentiment Signal: Sell
Current Market Cap: A$5.82M
For an in-depth examination of NX1 stock, go to TipRanks’ Overview page.